Traduction de «potential years » (Néerlandais → Français) :

TERMINOLOGIE

afwijkend(e) | elektro-oculogram [EOG] | afwijkend(e) | elektromyogram [EMG] | afwijkend(e) | elektroretinogram [ERG] | afwijkend(e) | respons op zenuwstimulatie | afwijkend(e) | visually evoked potential [VEP]
Anomalies (de):électromyogramme [EMG] | électro-oculogramme [EOG] | électrorétinogramme [ERG] | potentiels évoqués visuellement | réponse à une stimulation nerveuse

potentiëring | versterking
potentiation/potentialisation | augmentation de l'action d'un médicament par l'absorption d'un second

potentie | kracht
1) puissance sexuelle - 2) efficacité | 1) puissance sexuelle - 2) d'un médicament

TRADUCTIONS EN CONTEXTE

Potential Years of Life Lost Resident Assessment Instrument Résumé Hospitalier Minimal - Minimale Ziekenhuisgegevens Rijksinstituut voor ziekte- en invaliditeitsverzekering – Institut national d’assurance maladie-invalidité- National Institute for Health and Disability Insurance
Patient Safety Indicator Potential Years of Life Lost Resident Assessment Instrument Résumé Hospitalier Minimal - Minimale Ziekenhuisgegevens Rijksinstituut voor ziekte- en invaliditeitsverzekering – Institut national d’assurance maladie-invalidité- National Institute for Health and Disability Insurance

This release contains forward-looking information about an agreement by Pfizer to acquire FoldRx, and about FoldRx’s product candidate tafamidis, its other clinical and preclinical development programs and its technology platform, including their potential benefits, that involves substantial risks and uncertainties. Such risks and uncertainties include, among other things, the satisfaction of conditions to closing the agreement; the uncertainties inherent in research and development; whether and when a new drug application for tafamidis will be filed with the FDA; decisions by regulatory authorities regarding whether and when to approve any drug applications that have been or may be filed for tafamidis and that may be filed for any other product candidates that may be generated by FoldRx’s technology platform as well as their decisions regarding labeling and other matters that could affect the availability or commercial potential of tafamidis and such other product candidates; and competitive developments. A further description of risks and uncertainties can be found in Pfizer’s Annual Report on Form 10-K for the fiscal year ended December 31, 2009 and in its reports on Form 10-Q and Form 8-K.
Such risks and uncertainties include, among other things, the satisfaction of conditions to closing the agreement; the uncertainties inherent in research and development; whether and when a new drug application for tafamidis will be filed with the FDA; decisions by regulatory authorities regarding whether and when to approve any drug applications that have been or may be filed for tafamidis and that may be filed for any other product candidates that may be generated by FoldRx’s technology platform as well as their decisions regarding labeling and other matters that could affect the availability or commercial potential of tafamidis and such other product candidates; and competitive developments.

- At the end of the follow-up and potential referral, the suicidal individuals are contacted again by telephone (provided they have agreed to this) after a period of one month / three months / six months / a year, in order to maintain contact and assess their general evolution.
- au terme du suivi et de l’orientation éventuelle, un contact téléphonique est repris avec le suicidant (pour autant qu’il ait manifesté son accord) à l’échéance d’un mois / trois mois / six mois / un an afin de maintenir le lien et jauger l’évolution générale de la personne.

In anticipation of changes to the product portfolio in the US, which includes expected approvals for a number of new specialty medicines but also the loss of market exclusivity for Diovan and other medicines in the next few years, Novartis has further streamlined its US business in Pharmaceuticals to maximize the potential of the changing portfolio in both primary care and specialty markets.
Novartis anticipe les changements qui vont intervenir au cours des années à venir dans son portefeuille de produits aux Etats-Unis, notamment les autorisations attendues pour de nouvelles spécialités mais aussi la perte de l’exclusivité du marché pour Diovan et d’autres médicaments. C’est ainsi que Pharmaceuticals a encore rationalisé ses opérations américaines pour maximiser le potentiel d’un portefeuille en plein changement, à la fois dans les soins de santé primaires et dans les marchés des spécialités.

NPC has been cooperating with parallel civil and criminal investigations by the EDPA into allegations of potential off-label marketing and promotion of the epilepsy therapy Trileptal as well as certain payments made to healthcare providers in connection with this medicine. Earlier this year, NPC entered into a plea agreement with the EDPA, which is contingent on court approval, to resolve criminal allegations.
NPC coopère aux investigations civiles et criminelles que l’EDPA mène en parallèle au sujet d’accusations de promotion de Trileptal, un traitement contre l’épilepsie, pour des indications pour lesquelles ce produit n’a pas été autorisé, et de certains paiements à des prestataires de soins de santé en lien avec ce médicament.

The potential use of Zometa for adjuvant breast cancer in premenopausal women is being reviewed by US and European regulatory authorities with feedback anticipated by year end.
L’utilisation possible de Zometa en tant qu'adjuvant au traitement du cancer du sein chez les femmes préménopausées est actuellement examinée par les autorités réglementaires américaines et européennes dont un avis est attendu avant la fin de cette année.